New combo therapy aims to stall colorectal cancer growth
NCT ID NCT07535632
First seen Apr 25, 2026 · Last updated May 22, 2026 · Updated 3 times
Summary
This study tests a new treatment for people with colorectal cancer that has spread and not responded to at least two prior therapies. Participants receive targeted radiation to tumors in the lung or liver, followed by a combination of three drugs: an immunotherapy (sintilimab), a blood vessel blocker (bevacizumab), and a chemotherapy pill (TAS-102). The goal is to see if this approach delays cancer growth compared to standard care. About 58 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.